NCT00823940 - A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2009

Primary Completion Date

April 27, 2009

Study Completion Date

April 27, 2009

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK1362885

5 - 100mg of GSK1362885 or placebo

DRUG

GSK1362885

100 - 600mg or placebo

DRUG

Glucagon

0.5mg IV bolus

DRUG

Glucagon + GSK1362885

0.5mg Glucagon IV bolus + selected dose of GSK1362885

Trial Locations (1)

GSK Investigational Site, Minneapolis